Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients
Subscribe To Our Newsletter & Stay Updated
